欧林生物A股定增失败后拟发H股 控股股东上月套现1亿

Core Viewpoint - The company, Olin Bio (688319.SH), is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and optimize its capital structure [1] Group 1: H-Share Listing Plans - Olin Bio is in discussions with relevant intermediaries regarding the H-share listing, with specific details yet to be determined [1] - The H-share listing will require approval from the company's board, shareholders, and various regulatory bodies including the China Securities Regulatory Commission and the Hong Kong Stock Exchange [1] Group 2: Previous A-Share Issuance Attempt - On August 31, Olin Bio announced the termination of its plan to issue A-shares through a simplified procedure due to current market conditions and company strategy [2] - The previous A-share issuance aimed to raise up to 300 million RMB, with a proposed subscription amount of 12,529.29 million RMB for specific investors [2] Group 3: Shareholder Changes - The controlling shareholder, Shanghai Wushan Biotechnology Co., Ltd., reduced its stake by 4.4028 million shares, realizing approximately 119.98 million RMB from the sale [4] - Following the reduction, the shareholding of Shanghai Wushan and its concerted parties decreased from 29.00% to 27.92% of the total shares [4] Group 4: Financial Performance - Olin Bio's revenue from 2021 to 2024 was reported as 487 million RMB, 548 million RMB, 496 million RMB, and 589 million RMB respectively, with net profits of 108 million RMB, 26.58 million RMB, 17.56 million RMB, and 20.76 million RMB [6]